An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogenic bone marrow transplantation

Bone Marrow Transplantation

Volumn 30, Issue 7, 2002, Pages 441-446

  Schots, R ^a   Van Riet, I ^a   Othman, T Ben ^b   Trullemans, F ^a   De Waele, M ^a   Van Camp, B ^a   Kaufman, L ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

Author keywords

Allogeneic BMT; C reactive protein; Severe complications; Transplant related mortality

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; CYCLOSPORIN; CYTOKINE ANTIBODY; DEFIBROTIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; ITRACONAZOLE; METHOTREXATE; METHYLPREDNISOLONE; NORFLOXACIN;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; BLOOD; BONE MARROW TRANSPLANTATION; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; ACUTE LEUKEMIA; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIINFLAMMATORY ACTIVITY; APLASTIC ANEMIA; BACTEREMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; ENDOTHELIUM LESION; GENDER; GRAFT VERSUS HOST REACTION; LIVER VEIN OBSTRUCTION; LIVING DONOR; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE DEPLETION; LYMPHOMA; MAJOR CLINICAL STUDY; MYELODYSPLASIA; MYELOMA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIBLING; SOLID TUMOR; T LYMPHOCYTE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BONE MARROW TRANSPLANTATION; C-REACTIVE PROTEIN; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INCIDENCE; INFLAMMATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036775475     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703672     Document Type: Article

References (27)

1. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087-1092.
2. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
3. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporin and methotrexate. Blood 1992; 80: 1838-1845.
4. Holler E, Roncarolo MG, Hintermeier-Knabe R et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 237-241.
5. Remberger M, Ringden O, Markling L. TNF-alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995; 15: 99-104.
6. Bacigalupo A, Oneto R, Bruno B et al, Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin. Bone Marrow Transplant 1999; 24: 653-659.
7. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. New Engl J Med 1999; 340: 448-454.
8. Schots R, Kaufman L, Van Riet I et al. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant 1998; 22: 79-85.
9. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multi-organ failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
10. Storb R, Thomas ED. Graft-versus-host disease in dog and man: The Seattle experience. Immunol Rev 1985; 88: 215-238.
11. Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor-alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
12. Vachino G, Gelfand JA, Atkins MB et al. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2- activated lymphocytes. Blood 1991; 78: 2505-2513.
13. Arber C, Passweg JR, Fluckiger U et al. C-reactive protein and fever in neutropenic patients. Scand J Infect Dis 2000; 32: 515-520.
14. Schots R, Trullemans F, Van Riet I et al. The clinical impact of early gram-positive bacteremia and the use of vancomycin after allogeneic bone marrow transplantation. Transplantation 2000; 69: 1511-1514.
15. Castell JV, Gomez-Lechon MJ, David M et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-1186.
16. Antin J, Ferrera J. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
17. Gugliotta L, Catani L, Vianelli N et al. High plasma levels of tumor necrosis factor-alpha may be predictive of veno-occlusive disease in bone marrow transplantation. Blood 1994; 83: 2385-2386.
18. Schots R, Van Riet I, Ben Othman T et al. A systemic inflammatory response involving C-reactive protein, interleukin-6, interleukin-8 and tumor-necrosis factor-alpha contributes to the development of hepatic veno-occlusive disease after allogeneic bone marrow transplantation. Blood 2001; 98 (Suppl. 1): 195a (Abstr. 816).
19. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 11: 3005-3020.
20. Khoury H, Adkins D, Brown R et al. Does early treatment with high-dose methylprednisone alter the course of hepatic regimen-related toxicity? Bone Marrow Transplant 2000; 25: 737-743.
21. Chopra R, Eaton JD, Grassi A et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122-1129.
22. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001; 344: 699-709.
23. Hervé P, Flesh M, Tiberghien P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362-3368.
24. Holler E, Kolb HJ, Mittermuller J et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor-alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890-899.
25. Racadot E, Milpied N, Bordigoni P et al. Sequential use of three monoclonal antibodies in corticosteroid-resistent acute GVHD: a multicentric pilot study including 15 patients. Bone Marrow Transplant 1995; 15: 669-677.
26. Verbon A, Dekkers PE, ten Hove T et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166: 3599-3605.
27. Hill GR, Crawford JM, Cooke KR et al. Total body irradiation and acute graft-versus-host disease: The role of gastro-intestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.